Diabetes: From Genes to Mechanisms to Medicines (J5)
January 23-27, 2028
| Fairmont Banff Springs, Banff, AB, Canada
Melina Claussnitzer, Mark I. McCarthy and Mark A Herman
| 1:00–6:00 PM |
Registration |
|
| 3:00–3:10 PM |
Welcome Remarks |
|
| 3:10–4:00 PM |
Keynote Address (Joint) |
|
| |
Sekar Kathiresan †, Verve Therapeutics
Building the Future of Cardiometabolic Therapeutics |
|
| 4:00–6:00 PM |
Cardiometabolic Crossroads, Converging Biology (Joint) |
|
| |
Naveed Sattar †, University of Glasgow
Diabetic Cardiomyopathy and HFpEF: Emerging Mechanisms and Clinical Endpoints |
|
| |
Philipp E. Scherer †, University of Texas Southwestern Medical Center
Adipose Tissue as an Endocrine Organ in Health and Disease |
|
| |
Carolyn L. Cummins, University of Toronto
Novel LXR Targets at the Heart of Cardiometabolic Disease |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 6:00–8:00 PM |
Welcome Reception |
|
Tuesday, January 25, 2028
| 8:00–11:15 AM |
Variant-to-Function in Cardiometabolic Disease: From Human Genetics to Disease Mechanism |
|
| |
Melina Claussnitzer, Broad Institute, Harvard Medical School and Massachusetts General Hospital
Genomic Mechanisms of Cardiometabolic Disease: A Path Toward Rationally Designed Therapeutics |
|
| |
Ines Cebola †, Imperial College London
From Hepatic Enhancer Landscapes to Diabetes Risk |
|
| |
Anna L. Gloyn †, Stanford University
Translating T2D Association Signals into Beta-Cell Biology |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:30–9:50 AM |
Coffee Break |
|
| 11:15–1:00 PM |
Poster Setup |
|
| 11:15–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 2:30–4:30 PM |
Symposia Spotlight 1 |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Heterogeneity, Endotyping, Precision Therapy |
|
| |
Miriam Udler †, Broad Institute of MIT and Harvard, Harvard Medical School, & Massachusetts General Hospital
The Many Faces of Type 2 Diabetes |
|
| |
Ruth J Loos †, University of Copenhagen
Obesity Through the Lens of Human Genetics |
|
| |
Andreas L Birkenfeld †, Helmholtz Munich and Universitätsklinikum Tübingen
Prediabetes Is Not One Disease: Mechanistic Subtypes and Targeted Prevention |
|
| |
Shivani Misra †, Imperial College London
Young-Onset Diabetes in Diverse Populations: Toward Precision Classification |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
Wednesday, January 26, 2028
| 8:00–11:00 AM |
Beyond Incretins (Sensitization, Thermogenesis, Novel Mechanisms) |
|
| |
David E. James †, University of Sydney
Systems-Level Insulin Signaling: From Phosphoproteomics to Mechanisms of Insulin Resistance |
|
| |
Mark A Herman, Baylor College of Medicine
Substrate-Driven Insulin Resistance: ChREBP and Therapeutic Targets Beyond Incretins |
|
| |
Lawrence Kazak †, McGill University
Non-Shivering Thermogenesis and Alternative Energy-Wasting Programs |
|
| |
Luca Lotta †, Regeneron Pharmaceuticals Inc.
From Human Genetics to Therapeutic Target: The INHBE-ACVR1C Axis in Body Fat Distribution and Metabolic Disease |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–1:00 PM |
Poster Setup |
|
| 11:00–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 3:00–4:30 PM |
Career Roundtable |
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Central Regulation and Energy Homeostasis |
|
| |
Martin Heni †, Ulm University
The Insulin-Resistant Brain: Central Regulation of Glucose and Lipid Metabolism |
|
| |
Tune H Pers †, University of Copenhagen
Human Genetics of Brain Regulation and Energy Homeostasis |
|
| |
Sadaf Farooqi †, University of Cambridge
Genes, Circuits, and Human Energy Balance: Lessons from Monogenic Obesity |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
Thursday, January 27, 2028
| 8:00–11:00 AM |
Novel Translational Endpoints in Diabetes and its Complications |
|
| |
Katalin Susztak †, University of Pennsylvania
Genetic and Epigenomic Drivers of Diabetic Kidney Disease: Toward Precision Nephrology |
|
| |
Jane E Reusch †, Rocky Mountain Regional VA Medical Center/ University of Colorado, Denver
Exercise Intolerance and Microvascular Dysfunction in Diabetes: Mechanisms and Endpoints |
|
| |
Akrit Sodhi †, Johns Hopkins University
HIF Signaling and Neovascularization in Diabetic Retinopathy: From Mechanism to Therapeutic Target |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–5:00 PM |
On Own for Lunch |
|
| 2:30–4:30 PM |
Symposia Spotlight 2 |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–6:45 PM |
Genetics-Driven Trial Enrichment and Target Validation (Joint) |
|
| |
Mark I. McCarthy, Genentech
From Human Genetics to Clinical Translation |
|
| |
Anthony Andrew Philippakis †, Google Ventures
AI and the Future of Therapeutics |
|
| |
Pradeep Natarajan †, Amgen
Polygenic Risk Scores for Trial Enrichment in Cardiovascular and Metabolic Disease |
|
| |
Beryl Cummings †, Marea Therapeutics
ANGPTL4 as a Validated Cardiometabolic Target: From Population Genetics to the Clinic |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 6:45–7:00 PM |
Meeting Wrap-Up: Outcomes and Future Directions |
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 PM |
Entertainment |
|
